Cellectis

57 articles with Cellectis

• Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting

  3/14/2023

  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS) today announced that preclinical data exploring purposeful armoring of CAR T-cells to enhance efficacy of MUC1 CAR T-cells in targeting triple-negative breast cancer, will be presented at the American Association of Cancer Research (AACR) Annual Meeting, to be held in Orlando, Florida on April 14-19, 2023.

• Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

  3/8/2023

  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today provided a business update and announced its results for the fourth quarter of 2022, and full year ending December 31, 2022.

• Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023

  3/1/2023

  Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) today announced that it will report financial results for the fourth quarter and year-end 2022 ending December 31st, 2022, on Wednesday, March 8, 2023, after the close of the US market.

• Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares

  2/7/2023

  Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today.

• Cellectis Announces Pricing of Follow-On Offering - February 03, 2023

  2/3/2023

  Cellectis S.A. announces the pricing of its previously announced underwritten global offering by way of a capital increase of 8,800,000 American Depositary Shares.

• Cellectis Announces Launch of Follow-On Offering - February 02, 2023

  2/2/2023

  Cellectis S.A. announced the launch of a global offering of USD 22 million of its American Depositary Shares, each representing one ordinary share of Cellectis, nominal value €0.05 per share pursuant to an underwriting agreement, to be entered into by Cellectis, Jefferies LLC and Barclays Capital Inc.

• Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics

  1/20/2023

  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS) announced today that it has amended certain financial terms of the $20 million convertible note issued by its partner, Cytovia Therapeutics, LLC (“Cytovia”) in payment of the upfront collaboration consideration provided for pursuant to the research collaboration and non-exclusive license agreement between Cellectis and Cytovia.

• Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement

  1/17/2023

  Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (“Calyxt”), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the “Merger Agreement”), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction.

• Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities

  12/28/2022

  Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced that it has entered into a €40 million credit facility agreement with the European Investment Bank .

• Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

  12/22/2022

  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that for the first time, a patient was dosed in the United States with its in-house manufactured product candidate UCART22, and completed the 28 day DLT period on December 14th, 2022, without complication.

• Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

  12/13/2022

  Cellectis S.A. today will host a live webcast reviewing updated clinical data on its Phase 1/2a BALLI-01 clinical trial (evaluating UCART22) and on its Phase 1 AMELI-01 clinical trial (evaluating UCART123) that were presented in an oral session on December 12, 2022 at the 64th Annual Meeting of the American Society of Hematology (ASH).

• Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

  12/1/2022

  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will host a live webcast to review the Company’s clinical data on the AMELI-01 study (evaluating UCART123) presented at the ASH Annual Meeting, and provide a Company update, on December 13, 2022.

• Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)

  11/10/2022

  Cellectis published a manuscript in Frontiers Bioengineering and Biotechnology demonstrating the feasibility of efficient multiplex gene engineering using a combination of two different molecular tools: Cellectis’ TALEN® gene editing technology and a TALE-BE.

• Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022

  11/10/2022

  Cellectis today announced that preclinical data will be presented on TALEN®-edited smart CAR T-cells overcoming key challenges of targeting solid tumors at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.

• Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022

  11/3/2022

  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced the release of two abstracts, which were accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting taking place from December 10 to 13, 2022.

• Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022

  11/3/2022

  Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop potentially life-saving cell and gene therapies, announced its results for the three-month and nine-month periods ending September 30, 2022.

• Cellectis to Report Third Quarter 2022 Financial Results

  10/27/2022

  Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) today announced that it will report financial results for the third quarter ended September 30th, 2022, on Thursday, November 3rd, 2022, after the close of the US market.

• Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

  10/11/2022

  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS) announced today that the Company will present both an oral and poster at the European Society of Gene and Cell Therapy’s (ESGCT) 29th Congress, to be held in Edinburgh from October 11-14, 2022.

• Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

  10/5/2022

  Cellectis announced today that pre-clinical data on TALEN ® -edited smart CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), to be held in Boston, M.A.

• Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer

  9/28/2022

  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Mark Frattini, M.D., Ph.D., as Chief Medical Officer, effective immediately.